Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
Verastem, Inc. (VSTM), a Delaware corporation, filed this Current Report on Form 8-K on November 13, 2025. The filing details a significant capital raise event involving an underwritten public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: The Company entered into an underwriting agreement with Jefferies LLC and Guggenheim Securities, LLC.
- Securities Issued:
- 8,543,794 shares of Common Stock (Firm Shares).
- Pre-Funded Warrants to purchase up to 3,870,000 shares of Common Stock.
- 1,862,069 additional shares (Option Shares) purchased by underwriters upon full exercise of their option on November 14, 2025.
- Offering Price: $7.25 per share of Common Stock; $7.2499 per Pre-Funded Warrant.
- Net Proceeds: Approximately $96.9 million, after deducting underwriting discounts, commissions, and estimated offering expenses.
- Closing Date: Expected on or about November 17, 2025.
Material Changes and Transaction Terms
This filing represents a material change in the Company's capital structure and liquidity position. The transaction was executed pursuant to a shelf registration statement on Form S-3 (File No. 333-275408) declared effective on November 20, 2023. The Pre-Funded Warrants have an exercise price of $0.0001 per share, do not expire, and are exercisable in cash or cashless. Exercise limitations apply to prevent beneficial ownership from exceeding 4.99%, 9.99%, or up to 19.99% (with notice) of outstanding shares.
Outlook, Risks, and Management Commentary
The Company intends to use the net proceeds to fund its operations and clinical development programs, though specific allocation details are not provided in this excerpt. The closing is subject to customary conditions. The filing includes standard representations, warranties, and indemnification obligations under the Securities Act of 1933. Legal counsel Ropes & Gray, LLP has issued an opinion regarding the validity of the securities.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $96.9 million net proceeds receipt.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific use of proceeds and covenants.
- Examine the Form of Pre-Funded Warrant (Exhibit 4.1) for detailed exercise mechanics and conversion rights in the event of an acquisition.
- Monitor the Company's subsequent filings for updated cash balance and dilution impact on existing shareholders.